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Abstract
Background
Relative effect of therapies indicated for the treatment of advanced renal cell carcinoma
(aRCC) after failure of first line treatment is currently not known. The objective of the present
study is to evaluate progression-free survival (PFS) and overall survival (OS) of cabozanti-
nib compared to everolimus, nivolumab, axitinib, sorafenib, and best supportive care (BSC)
in aRCC patients who progressed after previous VEGFR tyrosine-kinase inhibitor (TKI)
treatment.
Methodology & findings
Systematic literature search identified 5 studies for inclusion in this analysis. The assess-
ment of the proportional hazard (PH) assumption between the survival curves for different
treatment arms in the identified studies showed that survival curves in two of the studies did
not fulfil the PH assumption, making comparisons of constant hazard ratios (HRs) inappro-
priate. Consequently, a parametric survival network meta-analysis model was implemented
with five families of functions being jointly fitted in a Bayesian framework to PFS, then OS,
data on all treatments. The comparison relied on data digitized from the Kaplan-Meier
curves of published studies, except for cabozantinib and its comparator everolimus where
patient level data were available. This analysis applied a Bayesian fixed-effects network
meta-analysis model to compare PFS and OS of cabozantinib versus its comparators. The
log-normal fixed-effects model displayed the best fit of data for both PFS and OS, and
showed that patients on cabozantinib had a higher probability of longer PFS and OS than
patients exposed to comparators. The survival advantage of cabozantinib increased over
time for OS. For PFS the survival advantage reached its maximum at the end of the first
year’s treatment and then decreased over time to zero.
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Conclusion
With all five families of distributions, cabozantinib was superior to all its comparators with a
higher probability of longer PFS and OS during the analyzed 3 years, except with the Gom-
pertz model, where nivolumab was preferred after 24 months.
Introduction
Kidney cancer is relatively rare, accounting for 2.4% of all cancers globally (GLOBOCAN 2012
data) [1;2]. Data on the number of patients with renal cell carcinoma (RCC) who are alive at a
certain point of time (disease prevalence) are scarce, mainly due to poor patient prognosis
making incidence a more frequently used metric for cancer epidemiology [3]. Globally, the
age-standardized incidence rate of RCC is 4.4 per 100,000 (data derived from population-
based registries across the world; GLOBOCAN, Cancer Incidence in Five Continents series)
[4]. In Europe, cancer registries report an age-standardized incidence rate of 12.1 per 100,000
for kidney cancer in general [2]. RCC is difficult to diagnose because it is generally asymptom-
atic or presents with unspecific symptoms at disease onset [5;6]. Delayed diagnosis results in a
considerable proportion (30%) of patients presenting with advanced disease [6].
In Europe, standard of care for advanced renal cell carcinoma (aRCC) consists of targeted
therapies that inhibit key signaling pathways involved in renal cell tumor genesis, specifically
the vascular endothelial growth factor receptor (VEGFR) and the mammalian target of rapa-
mycin (mTOR) pathways [7]. The European Association of Urology (EAU) recommends suni-
tinib or pazopanib as first line treatments for aRCC [8;9]. However, most patients progress on
the first line therapy and require subsequent treatment. Median time to progression under the
first line therapy is approximately 12 months [10]. Commonly used treatments after disease
progression are everolimus, axitinib and sorafenib, and more recently also nivolumab and
cabozantinib. From year 2005 onwards, targeted therapies, such as everolimus, axitinib and
sorafenib have been recommended in National Comprehensive Cancer Network (NCCN),
European Society for Medical Oncology (ESMO), and EAU guidelines for the second line
treatment of aRCC [7;11;12]. Nivolumab and cabozantinib were added to recent guideline
updates [8;9;12] after publication of results from the CheckMate025 and METEOR trials [13–
15]. In our network we consider studies that either directly or indirectly contribute to the
assessment of relative efficacy of cabozantinib compared to everolimus, axitinib, sorafenib,
nivolumab or best supportive care.
Due to lack of head-to-head comparisons of therapies for aRCC after failure of VEGFR-
therapy, the information regarding their comparative effectiveness is currently limited. Overall
survival (OS) under nivolumab and cabozantinib have been compared in a recent network
meta-analysis (NMA) [16] using data from the pivotal trials for each treatment [13;14]. Since
the publication of this study, more mature OS results for cabozantinib were published [15]. No
indirect treatment comparisons or NMAs were identified that compared cabozantinib with
axitinib, sorafenib or best supportive care. The recent National Institute for Health and Care
Excellence (NICE) single technology appraisal (STA) for nivolumab includes a NMA compar-
ing nivolumab to axitinib, everolimus and best supportive care (BSC) [17]. While Wiecek &
Karcher (2016) conducted a meta-analysis of full Kaplan-Meier (KM) data from publications
[16], the nivolumab STA presented a meta-analysis of hazard ratios (HRs). NMAs based on
HRs assume that the proportional hazard (PH) assumption holds for each pair of comparators,
that is, that HR between treatment arms does not change over time. In the nivolumab NICE
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STA, the HR NMA approach was used without formally testing for violation of PHs assump-
tion, and this was criticized by NICE. No additional analysis has been published using an alter-
native method. NMAs based on parametric curves compare the shape and scale parameters of
each distribution fitted to the survival curves, and do not assume PHs between the pairwise
comparators.
The objective of this study is to compare progression free survival (PFS) and OS and of
cabozantinib to everolimus, nivolumab, axitinib, sorafenib and BSC by using the NMA
method based on parametric survival curves as described by Ouwens et al. 2010 [18] and as
used by Wiecek & Karcher (2016) in their analysis of cabozantinib and nivolumab OS relative
gains [16]. Hence, this study will provide an update of the analysis done by Wiecek & Karcher
(2016) on the nivolumab versus cabozantinib OS comparison using mature OS data for cabo-
zantinib, while testing an additional distribution (log-normal). It will also provide the first
comparison of cabozantinib OS versus other treatments in second line treatment of aRCC.
Finally, to the authors’ knowledge, this study also provides the first PFS comparison of cabo-
zantinib and its comparators using the NMA method based on parametric survival curves.
These particular parametric survival distributions were chosen because they are typically
required in decision analytic models of cost-effectiveness as part of the health technology
assessment agency submissions, such as those for NICE.
Materials and methods
Study selection and data extraction
This systematic literature review aims to provide the evidence needed for the NMA. Search
strategies were designed to identify any studies on cabozantinib and possible comparators.
Based on the results of this broad systematic literature search, inclusion and exclusion criteria
were then applied for the selection of studies to inform the NMA. The PICOS framework guid-
ing the development of the search strategy is shown in Table 1 and further search parameter
restrictions are shown on Table 2. The details of databases searched are shown on Table 3. The
search protocol is presented in full in S2 File search protocol.
Table 1. Eligibility criteria of the systematic literature review.
Category Details
Population Patients with renal cell cancer (advanced / metastatic, previously treated)
Intervention Cabozantinib
Comparators Everolimus, axitinib, nivolumab, sorafenib, sunitinib, lenvatinib
Outcomes PFS
OS
Response rates
Drug discontinuation
Any other efficacy outcomes
Safety outcomes
Quality of life and other Patient-reported Outcomes
Biomarkers for efficacy and safety
Study Design RCT
https://doi.org/10.1371/journal.pone.0184423.t001
Table 2. Further parameter restrictions.
Category Details
Timeframe of Search No time restriction
Language No language restriction
https://doi.org/10.1371/journal.pone.0184423.t002
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Each of the records identified during the search was assessed for relevance against prede-
fined inclusion and exclusion criteria (Table 4). Copies of potentially relevant full papers were
obtained and further selection was undertaken based on full text review. Double independent
record selection was undertaken during screening of titles/abstract as well as full texts, and dis-
crepancies were resolved after discussion between reviewers or by a third reviewer.
To identify relevant evidence, a clear definition of the study participants, interventions,
comparison groups, outcomes and study types of interest was required. In order to ensure that
the included studies were sufficiently homogeneous to form part of a NMA, only prospective
comparative randomised controlled trials (RCTs) were included. Retrospective studies were
excluded from the review and NMA.
Trial selection for the network meta-analysis
For the NMA the following comparators were included: axitinib, everolimus, nivolumab, sora-
fenib, sunitinib and BSC/placebo. Studies with treatment which were not relevant for this
Table 3. Bibliographic databases searched.
Databases Date of
Search
Medline (includes Medline in Process and other non-indexed citations with status:
publisher, in-data review or Pubmed-not-Medline)
Jun 03, 2016
Embase Jun 03, 2016
Cochrane Library (includes Cochrane Central Register of Controlled Trials, Cochrane
Reviews, DARE, HTA Database, NHSEED)
Jun 03, 2016
https://doi.org/10.1371/journal.pone.0184423.t003
Table 4. Inclusion and exclusion criteria.
Clinical
effectiveness
Inclusion Criteria Exclusion Criteria
Population Patients with previously treated advanced or
metastatic renal cell carcinoma
Patients <18 years of age
Healthy subjects
Animal studies
Intervention The following interventions in the second- (and
further-) line setting:
• Cabozantinib (Cabometyx)
• Axitinib (Inlyta)
• Everolimus (Afinitor)
• Sorafenib (Nexavar)
• Sunitinib (Sutent)
• Lenvatinib (Kisplyx)
• Nivolumab (Opdivo)
Note: Combination therapies also possible
Interventions in the first-line setting
Comparators Any, including placebo and best supportive care
(BSC)
Radiotherapy, surgery and other non-pharmaceutical treatments
Outcomes • Overall survival
• Progression free survival
Patient-reported outcomes
Biomarker results
Safety results
Trial Design Randomised controlled trial (RCT)
Systematic reviews, meta-analyses, HTA for
screening of bibliographies only
Non-RCT
Comments, letters, editorials Non-systematic reviews
Timeframe All publication years
Language
restrictions
• English
• French
• German
• Italian
• Spanish
Publications with abstract in English but full text in language other than listed in
inclusion criteria will not be included but listed.
https://doi.org/10.1371/journal.pone.0184423.t004
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NMA were excluded unless they provide an intermediate link between cabozantinib, axitinib,
everolimus, nivolumab, sorafenib, sunitinib and BSC/placebo.
Statistical analysis
Patient level data for the METEOR study were provided by the study sponsor. For other stud-
ies in the evidence network, the method published by Guyot et al. [19] was used to estimate the
number of deaths and the number of patients censored every month from the published
Kaplan-Meier curves [14;20–22]. We carried out statistical analyses as well as used visual
inspection to assess whether the proportional hazards assumption is violated. We used tests
and graphs based on the Schoenfeld residuals and Therneau and Grambsch test.
The Bayesian NMA was implemented with the following five parametric survival functions:
log-normal, log-logistic, Weibull, Gompertz and exponential distributions, on the extracted PFS
and OS data, as described by Ouwens et al. 2010 [18]. The Bayesian approach was chosen because
it facilitates estimations on pooled data. A posterior probability distribution of this pooled relative
effect was obtained [18;23]. Fixed-effects models were considered for this analysis and additional
random-effects models were compared with fixed-effects models with purpose of heterogeneity
and inconsistency checking. Fixed-effects model and random-effects model are defined in S3 File
algorithms for fixed effect model and S4 File algorithms for random effect model. NMA compar-
ing HRs was also carried out. We compared the logarithms of HRs, as described by Caldwell
et al.[24]. Analysis was executed in R package netmeta using fixed effect model.
Bayesian estimation of survival parameters. Four of the models assumed two-parameter
distributions (log-normal, log-logistic, Weibull, Gompertz). One model assumed one-parame-
ter exponential distributions i.e. providing a fixed HR and hence assuming time-independent
hazard ratios. Model parameters were estimated using a Markov Chain Monte Carlo (MCMC)
method on WinBUGs [23]. The WinBUGs sampler was run for 50,000 iterations with the first
25,000 iterations discarded as “burn-in”. Convergence of the chains was checked using the
Gelman-Rubin statistic [25]. Further details on the programming of the parametric survival
curves are provided in S5 File Programming code for NMA.
Under the verification of the transitivity for each applied distribution (S6 File transitivity
property) and the absence of heterogeneity or inconsistency in the network (S7 File Heteroge-
neity & inconsistency), Bayesian meta-analysis models were used to determine the difference
of treatment effects. Goodness of model fit is specified in S8 File Goodness of fit.
Results
Literature selection
The systematic literature search for RCTs on cabozantinib and 6 of its comparators retrieved
6,612 citations. After excluding duplicates (n = 1,033) and screening against inclusion/exclu-
sion criteria 5,182 titles/abstracts were excluded. 400 citations were found eligible for the
screening on full-text level. 95 of these 400 records were systematic reviews, meta-analyses or
health technology assessment (HTA). Reference lists of these publications were checked for
any further relevant studies. This process did not yield any additions. Of the 305 full-text arti-
cles 241 publications were excluded. Due to language restrictions two records were excluded:
both records were in Chinese with an English abstract. The abstracts indicated that both are
systematic reviews with meta-analysis. In total, 65 publications, referring to 19 different stud-
ies, were considered for potential inclusion into the NMA, as shown in the PRISMA chart in
Fig 1. 64 of the studies were identified through the systematic literature search. One additional
paper on the METEOR study was published after the date of the literature search, as shown in
the PRISMA chart (Fig 1), and included for further analysis.
Relative efficacy in second line advanced renal cell carcinoma
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Fig 1. PRISMA chart.
https://doi.org/10.1371/journal.pone.0184423.g001
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To perform a NMA, the studies must form a connected network. Network diagrams show-
ing which of the treatments and comparator treatments are linked for each outcome were
developed. In total 19 studies were identified for potential inclusion into the NMA. Multiple
publications reporting the same study were identified and grouped as associated references.
The primary RCT data sources identified in the systematic literature search are summarised in
Table 5. Of the identified studies, ten studies were excluded because these were comparisons of
everolimus or sorafenib to agents out of scope of this study: bevacizumab+sorafenib, GDC-
0980, MK2206, AZD2014, apitolisib, temsirolimus, dovitinib, BNC105P+everolimus, tivoza-
nib, lenvatinib, and lenvatinib + everolimus. These studies were excluded because they neither
contained comparison to a treatment of interest (cabozantinib, everolimus, nivolumab, axiti-
nib, sorafenib or best supportive care), nor did they provide a link between comparators that
would not otherwise have a common comparator. The studies that have been excluded for this
reason are: NCT01442090, NCT01239342, ZEBRA, DusrupTOR-1, ROVER, NCT02330983,
TIVO-1, GOLD, INTORSECT, NCT01136733 [26–35]. Further four studies were excluded
from the network meta-analysis: RECORD-3 [36], SWITCH [37], ESPN [38], and study by
Ratain et al. 2006 [39]. The main reason for exclusion was sequential study design. Table 6
below gives details of the further exclusions.
The NMA was planned on the endpoints PFS and OS. These are commonly selected as the
primary and secondary efficacy endpoints in oncology trials, including in trials with aRCC
population. Data were extracted by one person from the reports on a pre-defined extraction
template in excel. Data were sought and extracted for PFS and OS (mean median, associated
hazard ratios, and Kaplan-Meier data, plus all associated confidence intervals). Data availabil-
ity for OS and PFS hazard ratios and KM curves was assessed in all included trials.
Intent-to-treat (ITT) and cross-over results (in those trials where cross-over was present)
were identified for the OS endpoint. PFS can be measured by an independent review
Table 5. Primary RCT data sources included in the network evidence base.
Trial name Treatment arms Primary data source
METEOR Cabozantinib vs everolimus Choueiri et al. 2016 [15]
RECORD-1 Everolimus/BSC vs placebo/BSC Motzer et al. 2010 [20]
CheckMate025 Nivolumab vs everolimus Motzer et al. 2015 [14]
TARGET Placebo vs sorafenib Escudier et al. 2009 [21]
AXIS Axitinib vs sorafenib Rini et al. 2011 [22]
NCT01136733 Everolimus vs lenvatinib vs lenvatainib + everolimus Motzer et al. 2015 [35]
RECORD-3 Sorafenib vs sunitinib Motzer et al. 2014 [36]
SWITCH Sorafenib vs sunitinib Eichelberg et al. 2014 [37]
TIVO-1 Tivozanib vs sorafenib Motzer et al. 2013 [29]
DisrupTOR-1 Everolimus vs BNC105P+everolimus Pal et al. 2015 [31]
ESPN Everolimus vs sunitinib Tannir et al. 2014 [38]
GOLD Dovitinib vs sorafenib Motzer et al. 2014 [30]
INTORSECT Temsirolimus vs sorafenib Hutson et al. 2014 [27]
ROVER Apitolisib vs everolimus Powles et al. 2016 [33]
ZEBRA AZD2014 vs Everolimus Powles et al. 2016 [34]
NCT01239342 MK2206 vs everolimus Jonasch et al. 2013 [28]
NCT01442090 GDC-0980 vs everolimus Powles et al. 2014 [32]
NCT02330783 Bevacizumab+sorafenib vs sorafenib Guo et al. 2015 [26]
Ratain 2006 Sorafenib followed by sorafenib vs placebo Ratain et al. 2006 [39]
Key: BSC, best supportive care; vs, versus
https://doi.org/10.1371/journal.pone.0184423.t005
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committee (IRC) and investigators (INV). IRC assessment of disease progression was deemed
likely to lead to the least biases, and hence it was prioritised if available. INV-assessed PFS was
considered only in cases where IRC-assessed PFS was not available. In three of the included
studies (RECORD-1, TARGET and AXIS) PFS was measured in the interim analysis by the
IRC, and no further IRC-assessed updates were reported in subsequent publications. Further
publications reported final OS results, and in some studies PFS continued to be assessed by
INV. In these cases interim results for IRC-assessed PFS were used. In CheckMate025 study
(nivolumab versus everolimus) no IRC-assessed PFS could be identified. In the nivolumab
NICE single technology appraisal the manufacturer stated that disease assessment was not con-
ducted independently in CheckMate025. The stated reason was that the CheckMate025 trial
was designed with OS as primary endpoint, and independent review of secondary endpoints
was not deemed necessary, as per regulatory guidelines [40].
A key consideration for any NMA is whether the studies that have been identified are suit-
ably homogeneous to facilitate reliable comparison. This similarity comparison is achieved by
comparing selected data from candidate studies; covariates that act as relative treatment effect
modifiers must be similar across trials [41]. The similarity of the studies in each network was
assessed (Table 7). The availability of subgroup results for PFS and OS endpoints was also
assessed. The final network utilised in the NMA is presented in Fig 2. The network for OS and
PFS endpoints are the same.
There were differences between the included trials, as shown in Table 7. The main sources
of difference were presence/absence of a cross-over trial design (RECORD-1, TARGET), the
number and type of prior therapies as well as baseline prognostic scores (e.g. Memorial Sloan-
Kettering Cancer Center [MSKCC] score).
Cross-over is present in RECORD-1 and TARGET studies. Hence, cross-over has an impact
on cabozantinib vs axitinib and BSC comparisons. However, comparison to nivolumab is not
impacted by the cross-over issue. In the RECORD-1 trial the estimate for OS HR for everoli-
mus vs placebo (BSC) is 0.87 [0.65, 1.17] in ITT population and 0.60 [0.22, 1.65] once adjusted
to cross-over by using rank-preserving structural failure time (RPSFT) model published by
Korhonen et al. [43]. The RPSFT model relies on assumption of constant effect of active treat-
ment (in this case everolimus) in terms of relative survival time. Hence, the effect does not
depend on when active treatment was initiated. Since the method requires additional censor-
ing of patient data, the precision of the HR estimate is lower than for the ITT estimate. How-
ever, the method was shown to be preferable to simple adjustments, such as censoring of
patients at time of crossover [43]. It should be noted that one other possible approach has been
considered by Hollaender, using inverse probability of censoring weights and multivariate
Cox models [44]. Results in best multivariate model (ranked according to Akaike information
criterion) were HR = 0.47 [0.27, 0.82]. It relies on a strong (and un-testable) assumption of no
unmeasured confounders, therefore RPSFT model was preferred, but the implications of using
Table 6. Key methodological and clinical reasons for further exclusions.
Key methodological and clinical parameters supporting exclusion
RECORD-3 [36] • Sequential design and hence randomisation only for first-line treatment
• No PFS or OS data available for second line only
SWITCH [37] • Sequential design and hence randomisation only for first-line treatment
• Second line base line characteristics not reported
• No OS data for second line
ESPN [38] • Only non-clear cell patients included
• No blinding details available
Ratain 2006 [39] • No information on prior VEGFR therapies
https://doi.org/10.1371/journal.pone.0184423.t006
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Cox model adjustment are also discussed below. In the TARGET study, an analysis with cen-
soring of placebo-assigned patients who crossed over to sorafenib at the start of cross-over was
conducted in addition to the ITT analysis [21]. The adjustment methodology is simple censor-
ing of all cross-over patients.
Trials included in network of evidence for the analysis were different in number of allowed
prior therapies and the distribution of compounds in patient cohorts. In METEOR study more
than one prior therapy was allowed. Patients were included in the study if they had received at
least one previous VEGFR TKI (there was no limit to the number of previous treatments). In
CheckMate025 patients were eligible to participate if they had received one or two previous
regimens of antiangiogenic therapy. In RECORD-1, previous therapy with sorafenib, sunitinib
or both was allowed. TARGET study included patients if they had progressed after one sys-
temic treatment within the previous 8 months. AXIS study patients had previously received
one previous systemic first line regimen with a sunitinib-based, bevacizumab plus interferon-
alfa-based, temsirolimus-based, or cytokine-based regimen, which reflected regimens with reg-
ulatory approvals at the time of study design. In our study we only included the prior-sunitinib
sub-population, because it was considered more comparable to the baseline study population
of the METEOR study. Table 7 summarises the baseline prior therapies for each study and
shows the availability of results for subgroups of patients by prior therapy. For CheckMate025
results stratified by number of prior therapies received were identified in nivolumab NICE
Table 7. Assessment of similarity between identified studies and availability of outcomes and subgroup results.
Study type Prior therapies Prognostic score
(MSKCC)
Subgroup results available
by
METEOR [15] RCT: Yes
Phase: III
Double blinded: Open-
label
Design: parallel
1 prior VEGFR
Cabozantinib: 71%
Everolimus: 70%
2+ prior VEGFR
Cabozantinib: 29%
Everolimus: 30%
Favourable: 43–44%
Intermediate: 40–43%
Poor: 14–16%
Missing: 0%
Patient level data available
RECORD-1 [20] RCT: Yes
Phase: III
Double blinded: Yes
Design: cross-over
1 prior VEGFR
Everolimus: 74%
Placebo: 74%
2+ prior VEGFR
Everolimus: 26%
Placebo: 26%
Favourable: 28–29%
Intermediate: 56–57%
Poor: 14–15%
Missing: 0%
Prognostic score: Yes
Type of prior therapies: Yes
Number of prior therapies:
No
Cross-over adjusted: Yes
CheckMate025
[14]
RCT: Yes
Phase: III
Double blinded: Open-
label
Design: parallel
1 prior VEGFR [17]
Nivolumab: 72%
Everolimus: 72%
2 prior VEGFR
Nivolumab: 28%
Everolimus: 28%
Favourable: 35–36%
Intermediate: 49%
Poor: 15–16%
Missing: 0%
Prognostic score: Yes
Type of prior therapies: No
Number of prior therapies:
Yes
Cross-over adjusted: NA
TARGET [21] RCT: Yes
Phase: III
Double blinded: Yes
Design: cross-over
No prior VEGFR therapy was received among
patients.
Favourable: 45–53%[42]
Intermediate: 47–55%[42]
Poor: NR
Missing: NR
Prognostic score: No
Type of prior therapies: No
Number of prior therapies:
No
Cross-over adjusted: Yes
AXIS [22] RCT: Yes
Phase: III
Double blinded: Yes
Design: parallel
1 prior treatment Favourable: 28%
Intermediate: 36–37%
Poor: 33%
Missing: 2–3%
Prognostic score: No
Type of prior therapies: Yes
Number of prior therapies:
No
Cross-over adjusted: NA
Key: BSC, best supportive care; RCT, randomised controlled trial; PFS, progression free survival; IRC, independent review committee assessed; INV;
investigator assessed; vs, versus; MSKCC, Memorial Sloan-Kettering Cancer Center; NA, not applicable; NR, not reported.
https://doi.org/10.1371/journal.pone.0184423.t007
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single technology appraisal (Appendix A8, Figs 2–5 on page 301–304) [40]. Results were not
identified by type of prior therapies. For RECORD-1 stratified estimates were available for
PFS, but not OS. In the TARGET study publication no subgroup data were identified that
stratified results by number/type of prior therapies. AXIS study reported results by type of first
line therapy. Due to lack of consistency and availability of results across all trials in the net-
work, it is not possible to analyse results by prior therapy. In the METEOR study results were
consistent regardless of number of prior therapies (see Table 8). Available results for Check-
Mate025, RECORD-1, and AXIS studies are reported in Table 9, Table 10 and Table 11,
respectively. These tables illustrate the differences in reported information between the trials.
Evidence suggests that the number of prior therapies does not affect the relative efficacy of
cabozantinib vs everolimus. For OS, nivolumab vs everolimus in CheckMate025 shows consis-
tent results for patients with 1 and 2 prior therapies, although results were not statistically sig-
nificant in the subgroup who received 2 prior treatments.
The MSKCC prognosis score was commonly used to stratify PFS and OS estimates: PFS in
METEOR, RECORD-1 and AXIS and OS in METEOR and CheckMate025. TARGET trial did
not include any patient with poor MSKCC prognosis and no subgroup analysis was presented
by MSKCC prognosis. No subgroup result was identified for initial prognosis for AXIS study.
An overview of identified HRs by prognosis is shown on Table 12. The identified data does not
allow for recreating NMA for particular prognosis (poor/intermediate/favourable) neither
based on HRs nor KM plots, but qualitative assessment is possible.
In the METEOR study, OS results for subgroups of patients with intermediate/favourable
prognosis, in comparison with the overall population, suggest potential larger efficacy of cabo-
zantinib compared to everolimus. Subgroup results for patients with poor prognosis in Check-
Mate025 study, in comparison to the overall study population, suggest larger efficacy of
nivolumab compared to everolimus in this subpopulation. For PFS it can be noted that for
subgroups of patients with intermediate/favourable prognosis, in comparison with the overall
population, results suggest potential larger efficacy of cabozantinib compared to everolimus
Fig 2. Evidence network for meta-analysis (OS, PFS).
https://doi.org/10.1371/journal.pone.0184423.g002
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and of everolimus compared to placebo. As patients with poor prognosis were not included in
the TARGET study, excluding such patients from analysis might lead to PFS HR of cabozanti-
nib vs axitinib more favourable to cabozantinib, but data (TARGET trial intermediate/favour-
able subgroups) is missing to conduct such comparison quantitatively.
Fig 3. Fitted PFS based on the best fitting Bayesian fixed-effects model (log-normal) overlaid on extracted Kaplan-Meier (KM) data, with
shaded areas representing 95% credible intervals.
https://doi.org/10.1371/journal.pone.0184423.g003
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Risk of bias was assessed with an adapted checklist for RCTs as proposed by the Centre for
Reviews and Dissemination. Criteria for quality assessment included adequacy of randomiza-
tion method, allocation concealment, homogeneity of baseline characteristics between
Fig 4. Fitted OS based on the best fitting Bayesian fixed-effects model (log-normal) overlaid on extracted Kaplan-Meier data, with shaded
areas representing 95% credible intervals.
https://doi.org/10.1371/journal.pone.0184423.g004
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treatment groups and blinding. The study quality assessment was conducted by two indepen-
dent assessors. The quality assessment of included trials showed that demographic and base-
line characteristics were balanced between the treatment arms in all included studies. None of
the studies reported unexpected dropouts between study groups. All 5 studies reported intent-
to-treat (ITT) analysis and reported appropriate method to account for missing data. A poten-
tial risk of bias arises from investigators, participants and outcome assessors not being blind to
treatment allocation in all studies. Effective blinding can ensure that the compared groups
receive a similar amount of attention, ancillary treatment and diagnostic investigations. Blind-
ing is not always possible, however, and three of the studies were not double blinded:
• METEOR: Patients and investigators were not blinded to study treatment. A masked inde-
pendent radiology committee assessed progression-free survival, overall survival, tumour
response, duration of response, and changes on bone scans.
Table 8. Subgroup results–number of previous therapies received (METEOR).
Number of VEGFR TKIs PFS
Choueiri et al. 2016 [15]
OS
Choueiri et al. 2016 [15]
HR 95% CI HR 95% CI
1 0.52 0.41–0.66 0.65 0.50–0.85
2 0.51 0.35–0.74 0.73 0.48–1.10
Key: CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; TKI,
tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor
https://doi.org/10.1371/journal.pone.0184423.t008
Fig 5. Averaged OS curves over time derived from the log-normal fixed-effects model, adjusted to the baseline
from METEOR study, with shaded areas representing 95% credible intervals.
https://doi.org/10.1371/journal.pone.0184423.g005
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• CheckMate025: This was an open-label study. Patients and investigators were not blinded to
study treatment.
• AXIS: This was an open-label study. Patients and investigators were not masked to study
treatment. Progression-free survival and objective response rate were assessed by a masked
independent radiology review.
CheckMate025 was an open-label study with no IRC assessment of end-points such as pro-
gression-free survival. The lack of blinding of the INV may increase the risk that knowledge of
which intervention was received, rather than the intervention itself, affects outcome measure-
ment. The blinding of outcome assessors can be especially important for the assessment of sub-
jectively assessed outcomes.
Statistical analysis
The Schoenfeld residuals and Therneau and Grambsch tests indicate that the proportional
hazards assumption holds for METEOR, RECORD-1, and AXIS studies. However, the
assumption is violated in CheckMate025 and TARGET studied for both PFS and OS end-
points. Intent-to-treat (ITT) and cross-over results (in those trials where cross-over was pres-
ent) were identified for the OS endpoint. PFS can be measured by an independent review
committee (IRC) and investigators (INV). IRC assessment of disease progression was deemed
likely to lead to the least biases, and hence it was prioritized if available. INV-assessed PFS was
considered only in cases where IRC-assessed PFS was not available. In three of the included
studies (RECORD-1, TARGET and AXIS) PFS was measured in the interim analysis by the
IRC, and no further IRC-assessed updates were reported in subsequent publications. Further
publications reported final OS results, and in some studies PFS continued to be assessed by
INV. In these cases interim results for IRC-assessed PFS were used. In CheckMate025 study
(nivolumab versus everolimus) no IRC-assessed PFS could be identified. Table 13 shows the
details of data availability by endpoint.
Table 9. Subgroup results–number of previous therapies received (CheckMate025).
Number of VEGFR TKIs PFS OS
Motzer et al. 2015 [14]
HR 95% CI HR 95% CI
1 - - 0.71 0.56–0.90
2 - - 0.89 0.61–1.29
Key: CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; TKI,
tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor
https://doi.org/10.1371/journal.pone.0184423.t009
Table 10. Subgroup results–number of previous therapies received (RECORD-1).
Number of VEGFR TKIs PFS
Motzer et al. 2008[45]
OS
HR 95% CI HR 95% CI
Sorafenib only 0.29 - - -
Sunitinib only 0.30 - - -
Both 0.28 - - -
Key: CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; TKI,
tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor
https://doi.org/10.1371/journal.pone.0184423.t010
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Despite the violation of PH assumption, we carried out the comparison of HRs. The results
for OS and PFS are shown in Table 14 and Table 15, respectively.
We undertook a network meta-analysis comparing the relative efficacy of cabozantinib and
its comparators. Fixed-effects model was preferred to random-effects models for this analysis,
based on the preliminary evaluation of heterogeneity. The fixed-effects models provided as
good model fitting as the random-effects models (Table 16 and Table 17), but were more
robust against the choice of prior distributions. Moreover, the “burn-in” period was shorter
than that with the random-effects models.
Model fit statistics indicate that log-normal model provided the best statistical fit for both
OS and PFS—see Tables 14 and 15, respectively. While log-normal model provided the best
overall statistical fit for the whole network, the best statistical fit for each individual study var-
ied. The fitted PFS and OS curves were superimposed on the extracted Kaplan-Meier data
(Figs 3 and 4) to observe the visual fit of extracted data versus modelled data. Visually log-nor-
mal model provided a good fit for PFS and OS data across all treatments, with the exception of
PFS for sorafenib and axitinib. For the best fitting model (log-normal), PFS and OS for patients
under cabozantinib were predicted to be superior compared to all other treatments up to 36
months Figs 5 and 6). Other models (Weibull, Gompertz, log-logistic and exponential) showed
similar results, exception for the PFS endpoint under the Gompertz model where nivolumab
was preferred after 24 months (additional PFS and OS results are shown in S9 File Additional
results for fixed effect model (full network)). The estimated hazard ratios for cabozantinib ver-
sus other treatments became more favorable to cabozantinib over time; after the first month
for PFS and after the first four months for OS–see Figs 7 and 8.
Table 11. Subgroup results–number of previous therapies received (AXIS).
Number of VEGFR TKIs PFS
Rini et al. 2011 [22]
OS
Motzer et al. 2013[46]
HR 95% CI HR 95% CI
Sunitinib-containing regimen 0.741 0.574–0.958 0.997 0.782–1.270
Bevacizumab-containing regimen 1.147 0.573–2.295 Not reported Not reported
Temsirolimus-containing regimen 0.595 0.188–1.886 Not reported Not reported
Cytokine-containing regimen 0.462 0.318–0.673 0.813 0.555–1.191
Key: CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor; VEGFR, vascular
endothelial growth factor
https://doi.org/10.1371/journal.pone.0184423.t011
Table 12. Subgroup results–availability of HR results by prognostic score.
End-point Study Comparator Baseline HR for poor prognosis
[95% CI]
HR for intermediate prognosis
[95% CI]
HR for favourable prognosis
[95% CI]
OS CheckMate025 Nivolumab Everolimus 0.47
[0.30, 0.73]
0.76
[0.58, 0.99]
0.89
[0.59, 1.32]
OS METEOR Cabozantinib Everolimus 0.65
[0.39, 1.07]
0.67
[0.48, 0.94]
0.66
[0.46, 0.96]
PFS AXIS Axitinib Sorafenib 0.68
[0.49, 0.94]
0.80
[0.58, 1.10]
0.50
[0.33, 0.76]
PFS RECORD-1 Everolimus Placebo 0.44
[0.22, 0.85]
0.32
[0.22, 0.44]
0.31
[0.19, 0.50]
PFS METEOR Cabozantinib Everolimus 0.70
[0.42, 1.16]
0.47
[0.35, 0.62]
0.51
[0.38, 0.69]
Key: OS, overall survival; PFS, progression free survival, CI, confidence interval
https://doi.org/10.1371/journal.pone.0184423.t012
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Table 13. Sources of OS (ITT), OS (cross-over adjusted), PFS IRC-, and PFS INV-assessed KM plots and hazard ratio results.
HR (95% confidence
interval)
OS
ITT
OS
Cross-over
adjusted
PFS
Independent review committee
(IRC)
PFS
Investigator assessed (INV)
METEOR 0.66 (0.53–0.83)
Patient level data (published in Fig
2 [14])
Not applicable 0.51 (0.41–0.62)
Patient level data
(published in Fig 4 [14])
Not applicable
RECORD-1 0.87 (0.65–1.15)
Fig 6A [20]
0.60 (0.22–1.65)
Fig 5
0.30 (0.22–0.40)
Fig 2 [45]
Not applicable, IRC PFS
available
CheckMate025 0.73 (0.57–0.93)
Fig 1 [14]
Not applicable Not available 0.88 (0.75–1.03)
Fig 2B [14]
TARGET 0.88 (0.74–1.04)
Fig1A [21]
Fig 1B [21] 0.44 (0.35–0.55)
Fig 2C [47]
Not applicable, IRC PFS
available
AXIS** 0.997 (0.78–1.27)
Fig 2B [46]
Not applicable 0.741 (0.573–0.958) Fig 2C [22] Not applicable, IRC PFS
available
Key: OS, overall survival; ITT, intention to treat; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; KM, Kaplan-Meier; INV,
investigator assessed; IRC, independent review committee assessed.
Note
** prior-sunitinib group results used in the analyses.
Sources: [20] Motzer et al. 2010, [48] Korhonen et al. 2012, [45] Motzer et al. 2008, [14] Motzer et al. 2015, [21] Escudier et al. 2009, [47] Escudier et al.
2007, [46] Motzer et al. 2013, [22] Rini et al. 2011, [35] Motzer et al. 2015.
https://doi.org/10.1371/journal.pone.0184423.t013
Table 14. Network meta-analysis of OS HRs (cross-over adjusted, if applicable).
HR (95% credible intervals)
Axitinib Cabozantinib Everolimus Nivolumab Placebo Sorafenib
Axitinib NA 1.96
(0.68, 5.7)
1.3
(0.46, 3.67)
1.78
(0.62, 5.09)
0.78
(0.57, 1.07)
1
(0.79, 1.26)
Cabozantinib 0.51
(0.18, 1.48)
NA 0.66
(0.53, 0.83)
0.9
(0.69, 1.19)
0.4
(0.14, 1.09)
0.51
(0.18, 1.43)
Everolimus 0.77
(0.27, 2.19)
1.52
(1.21, 1.9)
NA 1.37
(1.17, 1.61)
0.6
(0.22, 1.62)
0.77
(0.28, 2.12)
Nivolumab 0.56
(0.2, 1.62)
1.11
(0.84, 1.46)
0.73
(0.62, 0.86)
NA 0.44
(0.16, 1.2)
0.56
(0.2, 1.57)
Placebo 1.29
(0.93, 1.77)
2.53
(0.91, 6.98)
1.67
(0.62, 4.49)
2.28
(0.84, 6.23)
NA 1.28
(1.04, 1.59)
Sorafenib 1
(0.79, 1.27)
1.97
(0.7, 5.57)
1.3
(0.47, 3.58)
1.78
(0.64, 4.97)
0.78
(0.63, 0.97)
NA
https://doi.org/10.1371/journal.pone.0184423.t014
Table 15. Network meta-analysis of PFS HRs (IRC-assessed when available, otherwise INV).
HR (95% credible intervals)
Axitinib Cabozantinib Everolimus Nivolumab Placebo Sorafenib
Axitinib NA 2.13
(1.32, 3.43)
1.09
(0.7, 1.68)
1.24
(0.78, 1.96)
0.33
(0.23, 0.46)
0.74
(0.58, 0.95)
Cabozantinib 0.47
(0.29, 0.76)
NA 0.51
(0.42, 0.62)
0.58
(0.45, 0.74)
0.15
(0.11, 0.22)
0.35
(0.23, 0.52)
Everolimus 0.92
(0.59, 1.42)
1.96
(1.62, 2.37)
NA 1.14
(0.97, 1.33)
0.3
(0.23, 0.4)
0.68
(0.48, 0.97)
Nivolumab 0.81
(0.51, 1.29)
1.73
(1.35, 2.21)
0.88
(0.75, 1.03)
NA 0.26
(0.19, 0.36)
0.6
(0.41, 0.89)
Placebo 3.07
(2.2, 4.28)
6.54
(4.65, 9.19)
3.33
(2.51, 4.42)
3.79
(2.75, 5.22)
NA 2.27
(1.83, 2.83)
Sorafenib 1.35
(1.05, 1.74)
2.88
(1.92, 4.31)
1.47
(1.03, 2.1)
1.67
(1.13, 2.46)
0.44
(0.35, 0.55)
NA
https://doi.org/10.1371/journal.pone.0184423.t015
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Discussion
Comparison of cabozantinib and its comparators is possible using both the NMA of constant
HRs and comparison of parametric survival curves, when considering data availability. In our
main analysis, we applied a Bayesian parametric NMA method to compare PFS and OS for
cabozantinib and its comparators over time using five families of distributions. Although PH
Table 16. Model fit statistics with PFS, fixed- and random-effects model.
Model fit statistics Weibull Gompertz Log-logistic Log-normal Exponential
FE RE FE RE FE RE FE RE FE RE
Residual deviance (Dbar) 6355.8 6355.3 6456.8 6456.3 6047.7 6047.9 5987.3 5987.0 6599.7 6600.1
Effective number of parameters (pD) 19.7 20.0 19.8 19.8 19.9 19.9 20.2 19.9 9.9 10.2
Deviance information criteria (DIC) 6375.5 6375.3 6476.6 6476.1 6067.6 6067.8 6007.5 6006.9 6609.6 6610.3
https://doi.org/10.1371/journal.pone.0184423.t016
Table 17. Model fit statistics with OS, fixed- and random-effects model.
Model fit statistics Weibull Gompertz Log-logistic Log-normal Exponential
FE RE FE RE FE RE FE RE FE RE
Residual deviance (Dbar) 4364.9 4364.8 4443.8 4344.0 4314.5 4314.3 4293.8 4293.4 4535.8 4536.3
Effective number of parameters (pD) 20.0 19.7 19.6 20.1 20.0 19.9 20.2 19.8 9.8 10.2
Deviance information criteria (DIC) 4384.9 4384.5 4463.4 4464.1 4334.5 4334.2 4314.0 4313.2 4545.6 4546.5
https://doi.org/10.1371/journal.pone.0184423.t017
Fig 6. Averaged PFS over time derived from the Log-normal fixed-effects model, adjusted to the baseline from
METEOR study, with shaded areas representing 95% credible intervals.
https://doi.org/10.1371/journal.pone.0184423.g006
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assumption was violated in the CheckMate025 and TARGET studies, we also carried out a
comparison of HRs as an alternative method.
A recent NICE STA for nivolumab included a NMA comparing nivolumab to everolimus,
axitinib, sorafenib and BSC [17]. This NMA was based on HRs, which we deemed an inappro-
priate approach due to violation of PHs assumptions. Regardless of the short-comings of the
chosen method in the nivolumab NICE STA, the findings were in line with this NMA; nivolu-
mab provided longer OS benefit compared to comparators other than cabozantinib. Wiecek &
Karcher (2016) on the other hand applied a Bayesian parametric survival NMA method in
order to compare OS for cabozantinib and nivolumab [16]. This analysis found that patients
on cabozantinib exhibited a lower hazard of death over nivolumab until the fifth month of
treatment, whereas patients on nivolumab exhibited a lower hazard of death after that time
point. However, these analyses were based on immature OS data from the METEOR trial [13],
and no superiority was found when the full data were incorporated [49].
The results of the HR NMA on the OS endpoint show a trend of improvement with cabo-
zantinib therapy versus axitinib, everolimus, nivolumab and best supportive care. No statisti-
cally significant difference between cabozantinib and its comparators were shown, with the
exception of comparison to everolimus. Cabozantinib differed significantly from its compara-
tors with regard to PFS improvement. The parametric model that best fitted both the PFS and
Fig 7. Estimated hazard ratios over time for cabozantinib vs other treatments for OS under log-normal
distribution, with solid line representing median and shaded areas representing 95% credible intervals.
https://doi.org/10.1371/journal.pone.0184423.g007
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OS data was the log-normal distribution. In this model, the estimated PFS and OS probabilities
for cabozantinib were 0.11 and 0.48 at 24 months. However, for its best comparator nivolu-
mab, those estimated survival probabilities were 0.04 and 0.43 respectively. The model that
provided the worst statistical fit to the data was found to be the exponential distribution,
which assumed a constant HR over time as in the traditional approach. It, thus, provided fur-
ther justification for our choice of model that did not require the PHs assumption. The results
of the HR NMA are consistent with the results of the survival curve NMA; the PFS for patients
receiving cabozantinib was predicted to be superior and the OS showed a trend towards
improvement (OS) compared to axitinib, everolimus, nivolumab and best supportive care.
In the Bayesian analysis, the fixed-effects model has been chosen and the random-effects
model has also been implemented for a sensitivity analysis, and heterogeneity & inconsistency
checking. Even if it enables estimation of an additional between-study covariance matrix, the
random-effects model returned quite similar comparison results to the fixed-effects model,
which proved the homogeneity and consistency of the NMA at the network level. In the Bayes-
ian framework, the fixed-effects model was favored because of its simplicity and robustness,
where “robustness” meant the quickly-reached convergence of simulated Markov chain. How-
ever, if experts’ opinion were available, random-effects model would have an advantage by per-
mitting the definition of a group of hyper-parameters which could reflect prior belief on the
Fig 8. Estimated hazard ratios over time for cabozantinib vs other treatments for PFS under log-normal
distribution, with solid line representing median and shaded areas representing 95% credible intervals.
https://doi.org/10.1371/journal.pone.0184423.g008
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study heterogeneity. In the Bayesian framework, informative prior distributions may have
improved the parameter estimation and reduced the uncertainty of estimation.
A limitation of the PFS analysis was the differing definitions of disease progression assess-
ment (investigator versus independent). Independent review committee PFS was not available
from CheckMate025 study, and hence investigator assessed PFS was used in this analysis in-
stead. The results of this analysis were reported over 36 months, while the data were extracted
from RCTs with shorter follow-up time. The OS in real-life may differ from the estimated OS,
given that the treatment persistence could differ from the persistence observed in the RCTs. A
possible direction for future work is to implement the generalized gamma distribution, which
includes various commonly used parametric survival distributions, such as Weibull, exponen-
tial, log-normal distributions. An improved model fit over Weibull or log-normal would then
be envisaged [50]. The NMA model extended the classical meta-analysis model by comparing
multiple studies with multiple arms. Provided that the network would remain connected, i.e.
neighbor studies shared a common treatment, new studies and treatments could be easily
added to the model and the approach remains feasible.
Conclusions
Our NMA reviewed and analyzed the existing literature for RCTs examining PFS and OS of
cabozantinib, everolimus, axitinib, sorafenib, nivolumab and best supportive care treatments
for aRCC in the second- and subsequent line settings. Our review has identified that cabozanti-
nib significantly improves PFS outcomes in aRCC. The results of our NMA did not show a sta-
tistical difference between cabozantinib and comparator therapies with regards to OS, except
when compared to everolimus. However, the results of the HR NMA and the parametric curve
NMA favored cabozantinib.
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